[Federal Register Volume 86, Number 21 (Wednesday, February 3, 2021)]
[Notices]
[Page 7989]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02234]


 ========================================================================
 Notices
                                                 Federal Register
 ________________________________________________________________________
 
 This section of the FEDERAL REGISTER contains documents other than rules 
 or proposed rules that are applicable to the public. Notices of hearings 
 and investigations, committee meetings, agency decisions and rulings, 
 delegations of authority, filing of petitions and applications and agency 
 statements of organization and functions are examples of documents 
 appearing in this section.
 
 ========================================================================
 

  Federal Register / Vol. 86, No. 21 / Wednesday, February 3, 2021 / 
Notices  

[[Page 7989]]



DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-04-2021]


Foreign-Trade Zone (FTZ) 22--Chicago, Illinois, Notification of 
Proposed Production Activity, AbbVie, Inc. (Pharmaceutical Products), 
North Chicago and Lake County, Illinois

    AbbVie, Inc. (AbbVie) submitted a notification of proposed 
production activity to the FTZ Board for its facilities in North 
Chicago and Lake County, Illinois. The notification conforming to the 
requirements of the regulations of the FTZ Board (15 CFR 400.22) was 
received on January 27, 2021.
    AbbVie already has authority to produce pharmaceutical products 
within Subzone 22S. The current request would add a finished product 
and a foreign status material to the scope of authority. Pursuant to 15 
CFR 400.14(b), additional FTZ authority would be limited to the 
specific foreign-status material and specific finished product 
described in the submitted notification (as described below) and 
subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt AbbVie from customs 
duty payments on the foreign-status materials/components used in export 
production. On its domestic sales, for the foreign-status materials/
components noted below and in the existing scope of authority, AbbVie 
would be able to choose the duty rates during customs entry procedures 
that applies to IMBRUVICA[supreg] tablets (duty-free). AbbVie would be 
able to avoid duty on foreign-status components which become scrap/
waste. Customs duties also could possibly be deferred or reduced on 
foreign-status production equipment.
    The material sourced from abroad is Ibrutinib active pharmaceutical 
ingredient (duty rate 6.5%). The request indicates that Ibrutinib is 
subject to duties under Section 301 of the Trade Act of 1974 (Section 
301), depending on the country of origin. The applicable Section 301 
decisions require subject merchandise to be admitted to FTZs in 
privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is March 15, 2021.
    A copy of the notification will be available for public inspection 
in the ``Reading Room'' section of the Board's website, which is 
accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at 
[email protected].

    Dated: January 28, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-02234 Filed 2-2-21; 8:45 am]
BILLING CODE 3510-DS-P